Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Interpatient Variability in Mesothelin Expression Necessitates Its Evaluation Before Gastric Cancer Immunotherapy Publisher Pubmed



Sotoudeh M1 ; Mansouri V2 ; Shakeri R3 ; Sharififard B3 ; Sajadi N4 ; Naderi M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Digestive Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Ali-Asghar Children's Hospital, Iran University of Medical Sciences, Tehran, Iran

Source: Immunotherapy Published:2022


Abstract

Aims: Mesothelin (MSLN) was applied for the immunotherapy of ovarian cancer and mesothelioma with a minimum expression of 60% to obtain a clinical response. Here, the authors evaluated MSLN expression as a potential target of gastric adenocarcinoma immunotherapy. Materials & methods: The expression of MSLN was evaluated by immunohistochemistry and was reported in primary tumor (PT) and metastatic tumor (MT) sites. Results: The results showed that only 17.1% and 13.5% of the patients had 60% or more MSLN expression in PT and MT sites, respectively. The expression of MSLN in PTs and MTs was not influenced by Lauren classification, neoadjuvant therapy or tumor stage. Conclusions: Interpatient variability in MSLN expression necessitates its evaluation before MSLN-based gastric cancer immunotherapy. © 2022 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Antxr1 (Tem8) Overexpression in Gastric Adenocarcinoma Makes the Protein a Potential Target of Immunotherapy, Cancer Immunology# Immunotherapy (2019)
2. Decoding the Expression Pattern of Muc3a in Gastric Adenocarcinoma: Unveiling the Key to Successful Immunotherapy, Expert Opinion on Therapeutic Targets (2023)
3. Msln (Mesothelin), Antxr1 (Tem8), and Muc3a Are the Potent Antigenic Targets for Car T Cell Therapy of Gastric Adenocarcinoma, Journal of Cellular Biochemistry (2019)
4. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
5. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
6. Combining Nanotechnology and Gas Plasma As an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication, Oxidative Medicine and Cellular Longevity (2021)
7. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications, Frontiers in Immunology (2017)
8. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (5)
Mahmood Naderi (3)
Other Related Docs
9. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
10. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
11. Survival Benefit of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Chemoradiation Versus Postoperative Treatment in Locally Advanced Gastric Cancer: A Retrospective Cohort Study, Journal of Gastrointestinal Cancer (2024)
12. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
13. Anti-Tumor Activity of Neratinib, a Pan-Her Inhibitor, in Gastric Adenocarcinoma Cells, European Journal of Pharmacology (2019)
14. Nanoformulations of Plant-Derived Compounds As Emerging Therapeutic Approach for Colorectal Cancer, Current Drug Delivery (2023)
15. Evaluation of the Anti-Tumor Effects of an Anti-Human Epidermal Growth Factor Receptor 2 (Her2) Monoclonal Antibody in Combination With Cd11b+/Gr-1+ Myeloid Cells Depletion Using a Recombinant Peptibody in 4 T1-Her2 Tumor Model, International Immunopharmacology (2023)
16. Tumor-Infiltrating Lymphocyte Therapy for Lung Cancer and Its Future Paradigms, Expert Opinion on Biological Therapy (2022)
17. Investigation of the Correlation Between Androgen Receptor and Zeb1 and Its Value in Progression of Gastric Cancer, Avicenna Journal of Medical Biotechnology (2020)
18. Implications for Pelvic Lymph Node Irradiation in Definitive Chemoradiotherapy of Node Negative Muscle Invasive Bladder Cancer Based on Predictive Factors of Clinicopathologic Discrepancy, Journal of Cancer Research and Clinical Oncology (2023)